Tissue Array
Log In | My Account | Cart (0 items) - $0.00
US Biomax, Inc.
 

CO951

Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases/95 cores, to be replaced by CO952
Unstained: $395.00 Add to Cart

Microarray Panel:Colon adenocarcinoma tissue microarray, duplicated cores, 30 cancer and 8 of which has matched normal adjacent tissue and 10 cases of matched metastasis, with follow-up data 2 cores per case
Cores:95
Cases:30
Layout:12 cols × 8 rows
Core Diameter:1.5 mm
Thickness:5 µm
Quality Control:Anti-Cytokeratin (CK) confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
123456789101112
A Rec Rec Sig Sig Asc Asc Tra Tra Sig Sig Asc Asc
B Sig Sig Des Des Rec Rec Asc Asc Des Des Cec Cec
C Sig Sig Asc Asc Asc Asc Tra Tra Asc Asc Sig Sig
D Asc Asc Sig Sig Sig Sig Sig Sig Rec Rec Sig Sig
E Rec Rec Sig Sig Sig Sig Cec Cec Tra Tra Asc Asc
F Lun Lun Lym Lym Ova Ova Lym Lym Lym Lym Lym Lym
G Ova Ova Lun Lun Ova Ova Lym Lym Sig Sig Asc Asc
H Asc Asc Rec Rec Des Des Asc Asc Sig Sig Sig Car
Legend: Asc - Ascending colon, Car - Carbon, Cec - Cecum, Des - Descending colon, Lun - Lung, Lym - Lymph node, Ova - Ovary, Rec - Rectum, Sig - Sigmoid colon, Tra - Transverse colon

- Carbon, - Malignant tumor (stage IIA), - Malignant tumor (stage IIIB), - Malignant tumor (stage IIIC), - Malignant tumor (stage IV), - Metastasis, - NAT

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Stage pTNM Months Type †
A1, A2 1 M 62 Rectum Adenocarcinoma, moderately differentiated IIIB T4N1M1 . Malignant
A3, A4 2 F 40 Sigmoid colon Adenocarcinoma, well differentiated IIIC T3N2M0 . Malignant
A5, A6 3 M 56 Ascending colon Adenocarcinoma, moderately differentiated IIIB T3N1M0 . Malignant
A7, A8 4 M 36 Transverse colon Adenocarcinoma, moderately differentiated IIIC T3N2M1 . Malignant
A9, A10 5 F 65 Sigmoid colon Adenocarcinoma, well differentiated IIA T3N0M0 . Malignant
A11, A12 6 M 62 Ascending colon Adenocarcinoma, moderately differentiated IIA T3N0M0 . Malignant
B1, B2 7 F 57 Sigmoid colon Adenocarcinoma, well differentiated IIIB T3N1M0 . Malignant
B3, B4 8 F – Descending colon Adenocarcinoma, well differentiated IV T4N1M1 . Malignant
B5, B6 9 M 45 Rectum Adenocarcinoma, well differentiated IIIB T3N1M0 . Malignant
B7, B8 10 M 65 Ascending colon Adenocarcinoma, well differentiated IIIB T3N1M0 . Malignant
B9, B10 11 F 63 Descending colon Adenocarcinoma, moderately differentiated IIIB T3N1M0 . Malignant
B11, B12 12 M 53 Cecum Adenocarcinoma, moderately differentiated IIIB T3N1M0 . Malignant
C1, C2 13 M 64 Sigmoid colon Adenocarcinoma, moderately differentiated IIIB T3N1M0 . Malignant
C3, C4 14 F 46 Ascending colon Adenocarcinoma, poorly differentiated IIIC T3N2M1 . Malignant
C5, C6 15 M 59 Ascending colon Adenocarcinoma, moderately differentiated IIA T3N0M0 . Malignant
C7, C8 16 M 42 Transverse colon Adenocarcinoma, moderately differentiated IIIC T3N2M1 . Malignant
C9, C10 17 F 49 Ascending colon Adenocarcinoma, moderately differentiated IIIC T3N2M0 . Malignant
C11, C12 18 M 76 Sigmoid colon Adenocarcinoma, moderately differentiated IV T3N1M1 . Malignant
D1, D2 19 M 74 Ascending colon Adenocarcinoma, moderately differentiated IIA T3N0M0 . Malignant
D3, D4 20 M 62 Sigmoid colon Adenocarcinoma, moderately differentiated IV T3N2M1 . Malignant
D5, D6 21 M 62 Sigmoid colon Adenocarcinoma, moderately differentiated IIA T3N0M0 . Malignant
D7, D8 22 F 56 Sigmoid colon Adenocarcinoma, moderately differentiated IV T3N2M1 . Malignant
D9, D10 23 F 75 Rectum Adenocarcinoma, well differentiated IIIB T3N1M0 . Malignant
D11, D12 24 F 41 Sigmoid colon Adenocarcinoma, well differentiated IV T4N2M1 . Malignant
E1, E2 25 M 51 Rectum Adenocarcinoma, moderately differentiated IIIC T4N2M1 . Malignant
E3, E4 26 F 47 Sigmoid colon Adenocarcinoma, moderately differentiated IV T4N1M1 . Malignant
E5, E6 27 M 68 Sigmoid colon Adenocarcinoma, moderately differentiated IIIB T3N1M0 . Malignant
E7, E8 28 F 65 Cecum Mucinous adenocarcinoma IIIC T3N2M1 . Malignant
E9, E10 29 M 61 Transverse colon Mucinous adenocarcinoma IIA T3N0M0 . Malignant
E11, E12 30 F 35 Ascending colon Mucinous adenocarcinoma IIA T3N0M0 . Malignant
F1, F2 31 M 66 Lung Metastatic adenocarcinoma from #1 . . 42 Metastasis
F3, F4 32 M 36 Lymph node Metastatic carcinoma from #4 . . 0 Metastasis
F5, F6 33 F – Ovary Metastatic adenocarcinoma from #8 . . 0 Metastasis
F7, F8 34 F 46 Lymph node Metastatic carcinoma from #14 . . 0 Metastasis
F9, F10 35 M 42 Lymph node Metastatic carcinoma from #16 . . 0 Metastasis
F11, F12 36 M 62 Lymph node Metastatic carcinoma from #20 . . 0 Metastasis
G1, G2 37 F 41 Ovary Metastatic adenocarcinoma from #24 . . 0 Metastasis
G3, G4 38 M 52 Lung Metastatic adenocarcinoma from #25 . . 17 Metastasis
G5, G6 39 F 47 Ovary Metastatic adenocarcinoma from #26 . . 0 Metastasis
G7, G8 40 F 65 Lymph node Metastatic carcinoma from #28 . . 0 Metastasis
G9, G10 41 F 40 Sigmoid colon Normal colon (match of #2) . . . NAT
G11, G12 42 M 56 Ascending colon Normal colon (match of #3) . . . NAT
H1, H2 43 M 62 Ascending colon Normal colon (match of #6) . . . NAT
H3, H4 44 M 45 Rectum Normal colon (match of #9) . . . NAT
H5, H6 45 F 63 Descending colon Normal colon (match of #11) . . . NAT
H7, H8 46 F 49 Ascending colon Normal colon (match of #17) . . . NAT
H9, H10 47 M 76 Sigmoid colon Normal colon (match of #18) . . . NAT
H11 48 M 62 Sigmoid colon Normal colon (match of #21) . . . NAT

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis


† For precise diagnosis, refer to pathology description.

Supplementary Data

Pos No. Follow-up months Follow-up result Cause of death Remark
A1, A2 1 67 dead cancer .
A3, A4 2 130 alive . .
A5, A6 3 30 dead cancer .
A7, A8 4 2 dead cancer .
A9, A10 5 125 alive . .
A11, A12 6 125 alive . .
B1, B2 7 125 alive . .
B3, B4 8 0 lost . .
B5, B6 9 0 dead cancer .
B7, B8 10 124 alive . .
B9, B10 11 124 alive . .
B11, B12 12 123 alive . .
C1, C2 13 123 alive . .
C3, C4 14 2 dead cancer .
C5, C6 15 35 dead cancer .
C7, C8 16 122 alive . .
C9, C10 17 122 alive . .
C11, C12 18 57 dead cancer .
D1, D2 19 122 alive . .
D3, D4 20 3 dead cancer .
D5, D6 21 121 alive . .
D7, D8 22 11 dead cancer .
D9, D10 23 121 alive . .
D11, D12 24 12 dead cancer .
E1, E2 25 105 alive . .
E3, E4 26 25 dead cancer .
E5, E6 27 60 dead cancer .
E7, E8 28 127 alive . .
E9, E10 29 124 alive . .
E11, E12 30 122 alive . .
F1, F2 31 22 dead cancer .
F3, F4 32 2 dead cancer .
F5, F6 33 0 lost . .
F7, F8 34 2 dead cancer .
F9, F10 35 122 alive . .
F11, F12 36 3 dead cancer .
G1, G2 37 12 dead cancer .
G3, G4 38 88 alive . .
G5, G6 39 25 dead cancer .
G7, G8 40 127 alive . .
G9, G10 41 . . . .
G11, G12 42 . . . .
H1, H2 43 . . . .
H3, H4 44 . . . .
H5, H6 45 . . . .
H7, H8 46 . . . .
H9, H10 47 . . . .
H11 48 . . . .

Find overlapping cases with this tissue array:
© 2003 - 2013 US Biomax Inc.   custsrv@biomax.us   Tel: (800) 935-1357 | Privacy Policy

Authorize.Net Seal Starfield Seal